Eiger Biopharmaceuticals (NASDAQ:EIGR) Stock Passes Above Fifty Day Moving Average of $10.52

Share on StockTwits

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)’s share price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $10.52 and traded as high as $11.47. Eiger Biopharmaceuticals shares last traded at $11.37, with a volume of 3,664 shares changing hands.

A number of equities research analysts have issued reports on EIGR shares. Wedbush reissued an “outperform” rating and set a $35.00 target price on shares of Eiger Biopharmaceuticals in a report on Tuesday, June 18th. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, August 13th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $28.00 price target on shares of Eiger Biopharmaceuticals in a research report on Monday, August 12th. Citigroup assumed coverage on Eiger Biopharmaceuticals in a research note on Wednesday, June 26th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, BidaskClub raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $28.34.

The stock’s fifty day moving average is $10.54 and its two-hundred day moving average is $11.60. The company has a current ratio of 9.64, a quick ratio of 9.64 and a debt-to-equity ratio of 0.36. The firm has a market cap of $269.68 million, a P/E ratio of -2.93 and a beta of 1.04.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). On average, analysts forecast that Eiger Biopharmaceuticals Inc will post -2.51 EPS for the current year.

A number of large investors have recently bought and sold shares of EIGR. Bank of America Corp DE increased its stake in shares of Eiger Biopharmaceuticals by 49.6% in the fourth quarter. Bank of America Corp DE now owns 25,884 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 8,581 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Eiger Biopharmaceuticals in the fourth quarter valued at $255,000. Laurion Capital Management LP raised its stake in shares of Eiger Biopharmaceuticals by 126.5% during the 1st quarter. Laurion Capital Management LP now owns 114,038 shares of the biotechnology company’s stock valued at $1,594,000 after purchasing an additional 63,696 shares during the period. Sanders Morris Harris LLC bought a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $344,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at $113,000. 84.67% of the stock is owned by institutional investors.

Eiger Biopharmaceuticals Company Profile (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Read More: Limitations of the P/E Growth ratio

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.